Medivir AB

As of June 30, 2026, Medivir AB carries a market capitalization of 1.09B, placing it among publicly traded companies globally. Its enterprise value stands at 839.02M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medivir AB's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Medivir AB has 617.94M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 71.44, and the price-to-book ratio stands at 3.69.

These figures are as of June 30, 2026. The EV/Sales ratio of 97.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 839.02M versus a market cap of 1.09B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Medivir AB maintains a current ratio of 8.49, meaning it holds 8.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Medivir AB posted a negative return on equity (ROE) of -46.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -36.52, reflecting losses generated across the asset base. The company generates approximately 860,000.00 in revenue per employee across its workforce of 10.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Medivir AB's stock has gained approximately 197.03% over the past 52 weeks. The 50-day moving average sits at 1.71, while the 200-day moving average is 1.66.

Over the twelve months ended June 30, 2026, Medivir AB generated 8.60M in revenue and converted that into -87.30M in net income, yielding earnings per share of -0.25. EBITDA reached -54.80M, while operating income came in at -87.60M.

These figures are as of June 30, 2026. Total book value stands at 295.80M, with working capital of 228.50M providing operational flexibility.

Medivir AB produced -51.70M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -1,018.60 and net profit margin of -1,015.12 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.41: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -24.43, meaning Medivir AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Medivir AB's most recent stock split took place on December 4, 2023 with a 68:83 split ratio.

As of June 30, 2026, Medivir AB has an Altman Z-Score of 13.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.